Paul Ashton is President and Chief Executive Officer of pSivida (MA, USA), a provider of miniaturized, sustained-release drug-delivery products with a primary focus in ophthalmology. He also served in this role at Controlled Delivery Systems, a company he co-founded in 1991. Prior to this, he was a joint faculty member at the University of Kentucky (KY, USA), faculty member at Tufts University (MA, USA) and pharmaceutical scientist at Hoffman-La-Roche (Basel, Switzerland). Dr Ashton spoke to Therapeutic Delivery about the progress and challenges of sustained-release drug delivery to the eye, both within and outside pSivida.
Interview conducted by James Potticary, Assistant Commissioning Editor.